My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Abbott Laboratories (NY:ABT)

104.95 +2.61 (+2.55%)

Delayed Quote Updated: 10:54 AM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9

...

52 53 Next >

The Market Is Flashing Warning Signals Not Seen in Years. Here’s Why I Just Bought 3 of SCHD’s Dividend Kings. ↗

October 13, 2026

The market's warning signs are driving me to shift my portfolio towards high-quality holdings.

Via The Motley Fool

Topics ETFs Economy

Want Passive Income for Life? Here Are 2 Dividend Stocks to Buy and Never Sell ↗

October 12, 2026

These companies have a long history of dividend growth.

Via The Motley Fool

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 12, 2026

Abbott trades at a 18x forward P/E with $7.4B in free cash flow, while Intuitive Surgical commands a 39x multiple backed by zero debt and 20% revenue growth.

Via The Motley Fool

Abbott Laboratories (NYSE:ABT): A Quality Stock With Durable Fundamentals ↗

October 12, 2026

Via Chartmill

Abbott Laboratories (NYSE:ABT) Clears All Quality Investing Hurdles ↗

August 26, 2026

Via Chartmill

AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway. ↗

October 11, 2026

A super-high yield isn't everything.

Via The Motley Fool

Topics Intellectual Property

How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? ↗

October 10, 2026

You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.

Via The Motley Fool

Topics Intellectual Property

History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio. ↗

October 10, 2026

Abbott has a low-risk profile with significant upside potential.

Via The Motley Fool

These 3 Dividend Stocks Yield Less Than 10-Year Treasuries Over 5%. Here's Why They Are Better Buys Anyway. ↗

October 01, 2026

Treasuries pay more today, but these three healthcare dividend payers offer something Treasuries can't: growth in both the payout and the stock.

Via The Motley Fool

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 01, 2026

Intuitive Surgical is beating estimates and raising margins while its installed base keeps expanding. Abbott is executing steadily across a diversified portfolio but growing at a more measured pace.

Via The Motley Fool

Want a Portfolio That Pays You $1,000 a Month in Passive Income? This Dividend ETF Could Get You There. ↗

September 24, 2026

It's as stable and consistent as you'd hope from a dividend ETF.

Via The Motley Fool

Topics ETFs

Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade ↗

September 24, 2026

It would be hard for investors to replicate the company's return over the past decade.

Via The Motley Fool

Topics Intellectual Property

3 High-Yielding Dividend Stocks That Are No-Brainer Buys for Retirees and Risk-Averse Investors ↗

September 22, 2026

These quality, low-volatility stocks yield between 2.4% and 3.1%, and have been raising their payouts for decades.

Via The Motley Fool

Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth ↗

September 21, 2026

Abbott leads in absolute revenue, but Intuitive Surgical's growth rate tells a different story over the past eight quarters.

Via The Motley Fool

Topics Product Recall

3 Dividend Stocks to Buy and Hold for 10 Years ↗

September 18, 2026

They have a knack for increasing their dividends even when facing challenges.

Via The Motley Fool

Topics Intellectual Property

Why Wall Street Is Becoming Even More Bullish About This Dividend King ↗

September 18, 2026

Analysts keep raising their price targets on this 54-year dividend raiser. Here are the reasons behind the newfound confidence.

Via The Motley Fool

JEPI and JEPQ Yield Way More Than SCHD, but SCHD Could Produce More Passive Income Over the Long Term. Here's Why. ↗

September 17, 2026

Long-term holders of the Schwab U.S. Dividend Equity ETF have seen their yield on cost gradually rise.

Via The Motley Fool

Topics Bonds ETFs Regulatory Compliance

Is AbbVie the Best Dividend King to Buy in September? ↗

September 16, 2026

It is certainly a good Dividend King to buy in September.

Via The Motley Fool

Topics Intellectual Property

SCHD's Stunning Reversal: Schwab's Flagship Dividend ETF Is Up 29% and Climbing ↗

September 13, 2026

Given what's going on in the world and in the market, perhaps it's natural that SCHD is surging.

Via The Motley Fool

Topics Artificial Intelligence ETFs World Trade

If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend King ↗

September 08, 2026

Worried about a pullback? This Dividend King pairs a 54-year streak with catalysts that could provide income even if the market crashes.

Via The Motley Fool

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗

September 06, 2026

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

Via MarketBeat

Topics Artificial Intelligence Bonds

3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King) ↗

September 05, 2026

Owning these dividend stocks could be a simple way to make money over the long term.

Via The Motley Fool

Topics Intellectual Property

If the AI Boom Slows Down, History Says This Is the Smartest Way to Protect Your Long-Term Portfolio ↗

September 02, 2026

The Schwab US Dividend Equity ETF is a safe all-weather investment.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Just Starting Out With $5,000? 3 Magnificent ETFs to Buy in 2026. ↗

August 31, 2026

These 3 ETFs would give you a strong long-term portfolio to build from.

Via The Motley Fool

Topics ETFs

Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy. ↗

August 26, 2026

His AbbVie purchase was a big move into a high-yielding dividend stock.

Via The Motley Fool

Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead. ↗

August 24, 2026

AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.

Via The Motley Fool

Topics Intellectual Property

Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson? ↗

August 23, 2026

These two high-quality dividend payers have had very different fortunes recently.

Via The Motley Fool

Topics Lawsuit

Recent Report Shows That Rep. Rick Allen Sold Up to $50K Worth of Abbott Laboratories Stock ↗

August 19, 2026

An official report on August 18, 2026 reveals Representative Rick Allen's recent sale of Abbott Laboratories (NYSE:ABT) stock, valued between $15,001 and $50,000. The transaction took place on July 14,...

Via Benzinga

If You Invest $100 a Month in SCHD, Here's the Passive Income It Could Deliver in 20 Years ↗

August 17, 2026

This top dividend ETF is still a reliable long-term income investment.

Via The Motley Fool

Topics ETFs Retirement Stocks

Recent Report Shows That Rep. Richard Dean Dr McCormick Sold Up to $375K Worth of Abbott Laboratories Stock ↗

August 17, 2026

Records from August 14, 2026 indicate that Representative Richard Dean Dr McCormick of Georgia made a sale of Abbott Laboratories (NYSE:ABT), valued between $25,025 and $375,000, with the transaction...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

52 53 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.